MNOVNGMHealthcare·Biotechnology#400 in industry

MediciNova, Inc.

Reports in 16d· 2026-05-13

-25.5% · 90d

$1.37

+0.00 (+0.00%)

After-Hours $1.37(+0.00)

News

(1)

April 2026

Apr 20, 20261 week agoPRER14AHealthcare

MNOV increases authorized shares from 100 million to 247 million total

MNOVMEDICINOVA INC

# 📄 What This Proxy Statement Is 📜 This document is an Amended Preliminary Proxy Statement (PRER14A), which is required by the SEC before a major annual gathering of stockholders. Think of this as the official instruction manual and agenda for the 2026 Annual Meeting of Stockholders. The goal is

Read summaryView on SEC EDGAR

Key Data

Market Cap$67.4M

Open$1.39

Prev Close$1.37

Day Range$1.37 – $1.40

52W Range$1.17 – $1.96

Volume44,604

P/E (TTM)—

EPS$-0.24

Dividend Yield—

Beta0.61

Price Target$9.00(+556.9%)

Next Earnings2026-05-13(16d)

Analyst Ratings

Strong Buy4 analysts

Buy 4Hold 0Sell 0

About

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Healthcare · Biotechnology

6 employees

medicinova.com